During the last decades, new treatments targeting disease mechanisms referred as
biologics have been introduced in the therapy of asthma and currently, five monoclonal …

Introduction Patients with severe asthma experience a significant burden of symptoms,
disease exacerbations and medication side-effects. Severe asthma interferes with the …

Background: Biologics have become an increasingly important class of therapeutic
compounds in a variety of immune and/or inflammatory diseases. Patients with severe …

New therapeutic options for severe asthma have recently emerged, mostly in the form of
monoclonal antibodies (“biologicals”) targeting relevant inflammatory pathways. Currently …

Patients with uncontrolled severe persistent asthma have greater morbidity, greater use of
health care resources, and more impairment in health-related quality of life when compared …

Asthma is a multifaceted disease and is associated with significant impairment and risk, and
a therapeutic response that is highly variable. Although current treatments are usually …

Objective The use of biologics in severe asthma has made substantial strides in disease
management and fostered a personalized medicine approach; however, how, when, and …

Objective To review the structure, function, clinical utility, and safety of current biologic
targeted therapies being used for the treatment of asthma. Data Sources Medical literature …

Patients with moderate-to-severe asthma may now be treated using a variety of monoclonal
antibodies that target key inflammatory cytokines involved in disease pathogenesis. Existing …

Background In Japan, biologic therapy was initiated for patients with severe asthma in 2009.
In recent years, four biologics with different mechanisms of action have become available in …